首页> 外文OA文献 >Analysis of renal impairment in MM-003, a phase III study of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma

【2h】

Analysis of renal impairment in MM-003, a phase III study of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma

机译：MM-003肾功能不全的分析，这是pomalidomide联合小剂量地塞米松与高剂量地塞米松治疗难治性或复发性和难治性多发性骨髓瘤的III期研究

页面导航

摘要
著录项
相似文献
相关主题

摘要

status: published

机译：状态：已发布

著录项

作者
Weisel Katja C; Dimopoulos Meletios A; Moreau Philippe; Lacy Martha Q; Song Kevin W; Delforge Michel; Karlin Lionel; Goldschmidt Hartmut; Banos Anne; Oriol Albert; Alegre Adrian; Chen Christine; Cavo Michele; Garderet Laurent; Ivanova Valentina; Martinez-Lopez Joaquin; Knop Stefan; Yu Xin; Hong Kevin; Sternas Lars; Jacques Christian; Zaki Mohamed H; Miguel Jesus San;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献
专利

1. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma [J] . Katja C. Weisel, Meletios A. Dimopoulos, Philippe Moreau, Haematologica . 2016,第7期

机译：MM-003肾病的分析，这是pomalidomide +低剂量地塞米松与高剂量地塞米松对难治性或复发性和难治性多发性骨髓瘤的III期研究
2. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial [J] . MiguelJ.S., WeiselK., MoreauP., The lancet oncology . 2013,第11期

机译：复发性和难治性多发性骨髓瘤（MM-003）患者的Pomalidomide联合小剂量地塞米松与高剂量地塞米松的比较：一项随机，开放标签的3期临床研究
3. Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma | Haematologica [J] . Kevin W. Song, Meletios A. Dimopoulos, Katja C. Weisel, Haematologica . 2015,第2期

机译：MM-003在复发和/或难治性多发性骨髓瘤患者中进行的pomalidomide联合小剂量地塞米松与大剂量地塞米松的健康相关生活质量|血液学
4. THALIDOMIDE PLUS INTERMEDIATE-DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED AL PATIENTS [C] . Giovanni Palladini, Vittorio PerfettF, Stefano Perlini, International Symposium on Amyloidosis . 2005

机译：沙利度胺加上难治性/复发患者中的中间剂量地塞米松
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Analysis of renal impairment in MM-003 a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma [O] . Katja C. Weisel, Meletios A. Dimopoulos, Philippe Moreau, 2016

机译：MM-003的肾功能损害分析这是pomalidomide +低剂量地塞米松与高剂量地塞米松治疗难治性或复发性和难治性多发性骨髓瘤的III期研究
7. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma [O] . K. C. Weisel, M. A. Dimopoulos, P. Moreau, 2016

机译：MM-003中肾损伤分析，难治或复发和难治性多发性骨髓瘤中荷马三种+低剂量地塞米松的肾损伤。

Analysis of renal impairment in MM-003, a phase III study of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma

摘要

著录项

相似文献

相关主题

期刊订阅